• ECL Western Blotting Substrate: Technical Workflow and QC Gu

  2026-06-01

  ECL Western Blotting Substrate (SKU K2187) is designed for sensitive, nonradioactive detection of HRP-labeled proteins by chemiluminescence. It is ideal for Western blot assays in molecular, cancer biology, and signal transduction studies, but is not suitable for fluorescent or radioisotopic detection methods.

• Neuroligin 1, Striatal D2-MSNs, and Repetitive Behaviors in

  2026-06-01

  This study identifies the loss of Neuroligin 1 in striatal D2 medium spiny neurons as a driver of autistic-like repetitive behaviors through aberrant neuronal activation and downstream PKC overactivation. By dissecting the cellular and molecular mechanisms, the work clarifies how distinct neural activity patterns contribute to self-grooming and digging behaviors, laying groundwork for targeted interventions in ASD.

• Carvedilol Phosphate in Ischemia–Reperfusion Injury Models

  2026-05-31

  Carvedilol Phosphate is a high-purity non-selective beta blocker that empowers advanced modeling of ischemia–reperfusion injury (IRI) and GPCR signaling in cardiovascular and hepatic research. This guide translates recent mechanistic breakthroughs into actionable protocols, troubleshooting strategies, and workflow optimizations for preclinical investigators.

• Bortezomib (PS-341): Optimizing Proteasome Inhibition Workfl

  2026-05-30

  Bortezomib (PS-341) is a gold-standard proteasome inhibitor, offering precise control in apoptosis and cancer cell viability assays. This article delivers advanced workflow optimizations and troubleshooting for achieving reproducible results in proteasome-regulated cellular process research, highlighting critical protocol choices informed by recent evidence.

• InstaBlue Protein Stain Solution: Rapid Coomassie Gel Staini

  2026-05-29

  InstaBlue Protein Stain Solution addresses the need for ultra-fast, sensitive, and non-toxic visualization of proteins in polyacrylamide gels, eliminating time-consuming fixation and destaining steps. This reagent is ideal for workflows prioritizing speed, downstream compatibility, and environmental safety, but should not be substituted where alternative detection chemistries or pre-cast gel formats are mandatory.

• Homoharringtonine as a Rapid SARS-CoV-2 Inhibitor: Molecular

  2026-05-29

  A recent study demonstrates that homoharringtonine, a cytotoxic alkaloid previously established in leukemia research, rapidly clears SARS-CoV-2 from the upper respiratory tract in both animal models and human patients. These findings highlight its translational potential as a first-line antiviral intervention and establish a mechanistic bridge between oncology and infectious disease research.

• (S)-(+)-Dimethindene maleate: Protocols for M2 Antagonist Us

  2026-05-28

  (S)-(+)-Dimethindene maleate is a highly selective M2 muscarinic receptor antagonist with additional H1 histamine receptor blocking properties. This reagent addresses the need for precise modulation of muscarinic acetylcholine signaling in autonomic regulation research. It is not suitable for diagnostic or clinical applications and should be used solely for in vitro or ex vivo scientific studies.

• Partial β-Secretase Inhibition Reduces Amyloid Without Synap

  2026-05-28

  Satir et al. (2020) reveal that moderate inhibition of β-secretase can significantly reduce amyloid beta production without compromising synaptic transmission in neuronal cultures. This finding highlights the importance of dosing strategies in Alzheimer's disease research to minimize side effects while achieving therapeutic goals.

• (S)-(+)-Dimethindene maleate: Practical M2 Antagonist Guide

  2026-05-27

  (S)-(+)-Dimethindene maleate provides a selective M2 muscarinic receptor antagonist for pharmacological studies in autonomic regulation, cardiovascular, and respiratory physiology. It enables controlled receptor blockade where high specificity and solubility are required. This reagent is not suitable for diagnostic or therapeutic applications, and solutions should be used promptly after preparation for optimal assay reliability.

• Lactate-Driven Ran Lactylation Regulates Astrocyte Polarizat

  2026-05-27

  This study uncovers a novel mechanism by which lactate accumulation after spinal cord injury promotes astrocyte polarization via SIRT1-regulated lactylation of the non-histone protein Ran at lysine 123. These findings highlight an unappreciated link between metabolic signaling, nuclear transport, and glial cell fate, offering new angles for CNS repair research.

• Bufuralol Hydrochloride in β-Adrenergic Modulation Studies

  2026-05-26

  Bufuralol hydrochloride bridges traditional cardiovascular research and advanced hiPSC-derived organoid models, enabling translational pharmacokinetic insights. This guide delivers protocol enhancements, troubleshooting strategies, and practical applications for scientists leveraging APExBIO's trusted reagent.

• EZ Cap Cy5 Firefly Luciferase mRNA: Advancing 5-moUTP mRNA W

  2026-05-26

  Unlock dual-mode, high-efficiency gene expression and real-time delivery tracking with EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP). This next-generation reporter enables seamless transition between fluorescence-based mRNA tracking and bioluminescence translation assays, streamlining everything from delivery optimization to in vivo imaging.

• Cholesterol Hinders Lipid Nanoparticle Trafficking in Cells

  2026-05-25

  This study reveals that increasing cholesterol content in lipid nanoparticles (LNPs) impedes their intracellular trafficking and reduces nucleic acid delivery efficiency. Using a high-sensitivity tracking platform, the research clarifies the specific roles of LNP components in endosomal escape, offering actionable insights for the design of more effective gene delivery systems.

• JZL184: Optimizing Monoacylglycerol Lipase Inhibitor Workflo

  2026-05-25

  JZL184 stands out as a highly selective monoacylglycerol lipase inhibitor, enabling precise modulation of endocannabinoid signaling in both neuropharmacology and pain models. This guide delivers actionable protocols, troubleshooting strategies, and insights from the latest research, empowering researchers to push the boundaries of CB1-mediated pathway investigations.

• GLI2 Drives Tumor Immune Evasion via WNT and Prostaglandin P

  2026-05-24

  The reference study identifies GLI2 as a central transcriptional regulator enabling tumor immune evasion and resistance to immunotherapy by coordinating WNT ligand and prostaglandin signaling. These findings provide a mechanistic basis for targeting GLI2 to overcome immune checkpoint blockade resistance, offering translational guidance for combinatorial cancer therapies.

16421 records 1/1095 page Next 12345 下5页 Last page